132866-11-6
Chemical Structure
Lercanidipine hydrochloride
- CAS No.: 132866-11-6
- Formula:C36H42ClN3O6
- Molecular Weight:648.19
IUPAC Name: 3-(1-((3,3-diphenylpropyl)(methyl)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
InChIKey: WMFYOYKPJLRMJI-UHFFFAOYSA-N
SMILES: O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OC(C)(C)CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C.[H]Cl
Biological Activity: Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lercanidipine hydrochloride | 99.93% | Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lercanidipine hydrochloride (Standard) | ≥98% | Lercanidipine (hydrochloride) (Standard) is the analytical standard of Lercanidipine (hydrochloride). This product is intended for research and analytical applications. Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lercanidipine-13C,d3 hydrochloride | Lercanidipine-13C,d3 (hydrochloride) is the deuterium and 13C labeled Lercanidipine hydrochloride. Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lercanidipine-13C,d3-1 hydrochloride | Lercanidipine-13C,d3-1 (hydrochloride) is deuterium labeled Lercanidipine (hydrochloride). Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lercanidipine-d3 hydrochloride | 98.14% | Lercanidipine-d3 (hydrochloride) is the deuterium labeled Lercanidipine. Lercanidipine is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine has long lasting antihypertensive action and reno-protective effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70. [Content Brief]
- [2]. Duda-Seiman D, et al. Calcium Channel Blockers--Benefits Upon Vascular Biology in Hypertensive Patients. Cardiovasc Hematol Agents Med Chem. 2015;13(1):54-62. [Content Brief]
- [3]. Gupta S, et al. Neuroprotective effect of lercanidipine in middle cerebral artery occlusion model of stroke in rats. Exp Neurol. 2017 Feb;288:25-37. [Content Brief]
- [4]. Yeh JL, et al. Lercanidipine and labedipinedilol--A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities. Atherosclerosis. 2013 Feb;226(2):364-72. [Content Brief]
- [5]. Lee JJ, et al. Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats. Arch Pharm Res. 2010 Sep;33(9):1411-8. [Content Brief]
